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Co-Regulation and Interdependence of the
Mammalian Epidermal Permeability and
Antimicrobial Barriers
Karin M. Aberg1,2, Mao-Qiang Man1,2, Richard L. Gallo3, Tomas Ganz4, Debra Crumrine1,2, Barbara E.
Brown1,2, Eung-Ho Choi5, Dong-Kun Kim5, Jens M. Schro¨der6, Kenneth R. Feingold1,2 and Peter M. Elias1,2
Human epidermis elaborates two small cationic, highly hydrophobic antimicrobial peptides (AMP), b-defensin 2
(hBD2), and the carboxypeptide cleavage product of human cathelicidin (hCAP18), LL-37, which are co-packaged
along with lipids within epidermal lamellar bodies (LBs) before their secretion. Because of their colocalization,
we hypothesized that AMP and barrier lipid production could be coregulated by altered permeability barrier
requirements. mRNA and immunostainable protein levels for mBD3 and cathelin-related antimicrobial peptide
(CRAMP) (murine homologues of hBD2 and LL-37, respectively) increase 1–8 hours after acute permeability
barrier disruption and normalize by 24 hours, kinetics that mirror the lipid metabolic response to permeability
barrier disruption. Artificial permeability barrier restoration, which inhibits the lipid-synthetic response leading
to barrier recovery, blocks the increase in AMP mRNA/protein expression, further evidence that AMP expression
is linked to permeability barrier function. Conversely, LB-derived AMPs are also important for permeability
barrier homeostasis. Despite an apparent increase in mBD3 protein, CRAMP/ mice delayed permeability
barrier recovery, attributable to defective LB contents and abnormalities in the structure of the lamellar
membranes that regulate permeability barrier function. These studies demonstrate that (1) the permeability and
antimicrobial barriers are coordinately regulated by permeability barrier requirements and (2) CRAMP is
required for permeability barrier homeostasis.
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INTRODUCTION
The cutaneous permeability barrier, which allows survival in
the potentially desiccating terrestrial environment, and the
epidermal antimicrobial barrier, which prevents the vast
majority of exogenous pathogenic microorganisms from
colonizing and invading the skin, are considered discrete,
protective functions of mammalian skin (Elias et al., 2003).
Although permeability barrier homeostasis and the outer
antimicrobial shield both localize to the stratum corneum
(SC), a unique two-compartment tissue of anucleate, protei-
naceous corneocytes embedded in a lipid-enriched extra-
cellular matrix (reviewed in Elias and Menon, 1991), the
structural and biochemical basis for each differs. While the
hydrophobic, extracellular lipids impede transcutaneous
water loss (TEWL) (Grubauer et al., 1989a), it is the low
water content, acidic surface pH (Fluhr and Elias, 2002),
resident microflora, and certain surface-deposited proteins of
eccrine and sebaceous gland origin (Schittek et al., 2001;
Murakami et al., 2002), that comprise the outermost
antimicrobial shield (Schroder and Harder, 2006). Yet, also
present within human SC are at least four antimicrobial
peptides (AMP), that is the S100 protein, S100A7 (psoriasin),
RNase7, the cathelicidin (hCAP18) carboxy-terminal frag-
ment, LL-37, and human b-defensin2 (hBD2) (Elias, 2007)
(reviewed in Schro¨der, 2006). hBD2 and LL-37 serve not only
as AMP, but also as distal sensors of the innate immune
system (Fulton et al., 1997; Gallo and Huttner, 1998; Gallo
et al., 2002; Harder and Schroder, 2005; Lehrer, 2005;
Niyonsaba and Ogawa, 2005). Although expressed at
low levels under basal conditions, hBD2 and LL-37 are
inducible by UV-B, chronic inflammation, pathogen
challenge, and/or during wound healing (Frohm et al.,
1997; Liu et al., 2002; Heilborn et al., 2003; de Jongh
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Both hBD2 and LL-37 are packaged within a novel
secretory organelle, the epidermal lamellar body (LB) (Oren
et al., 2003; Braff et al., 2005), which delivers barrier lipids to
the SC interstices (Elias and Menon, 1991). Hence, we
hypothesized that these two functions could be linked (Elias,
2005; Elias and Choi, 2005), and explored the inter-relation-
ship between the cutaneous permeability and antimicrobial
barriers. We report here that these two functions are
coregulated specifically in response to permeability barrier
insults; and conversely, that at least one AMP, LL-37, is
required for normal permeability barrier homeostasis. To-
gether, these studies demonstrate that these two critical
defensive functions of SC are not disparate, but rather
interdependent processes.
RESULTS
Constitutive expression of both mBD3 and CRAMP in normal
epidermis
mRNA and protein levels of key synthetic enzymes of
cholesterol and fatty acid synthesis increase rapidly in the
underlying epidermis after acute permeability barrier disrup-
tion (Feingold, 1991). Hence, we first assessed the kinetics of
changes in epidermal cathelin-related antimicrobial peptide
(CRAMP)/mBD3 mRNA and protein levels after acute
permeability barrier disruption by repeated tape stripping.
Prior reports claim that both hBD2 and LL-37 are not
expressed in normal human epidermis (eg, de Jongh et al.,
2005). Yet, murine epidermis clearly demonstrates readily
detectible levels of both mouse b-defensin and CRAMP
protein in the outer epidermis by immunofluorescence
(Figure 1a and e). To insure that our antibodies were
detecting these peptides, we assessed CRAMP expression in
CRAMP/ epidermis, and found no detectible signal, while
the mBD3 antibody labels a single band in Western blots of
extracts of normal mouse epidermis (Figures S2 and S3).
Permeability barrier disruption upregulates mBD3 and CRAMP
expression
Prior studies have shown that acute barrier disruption (TEWL
rates 410normal) removes not only extracellular lipids
(Grubauer et al., 1989a), but it also co-extracts both
preformed mBD3 and CRAMP from SC (Elias and Choi,
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Figure 1. Acute permeability barrier disruption by tape stripping (TS) stimulates CRAMP and mBD3 expression; upregulation is blocked by occlusion.
Flanks of normal hairless mice (n¼ 3 in all groups) were sequentially tape stripped until TEWLX10-fold higher than in untreated controls. Tape-stripped
(TS) sites on some animals were immediately occluded with a vapor-impermeable (Latex) membrane. (a–h) Frozen sections (8 mm) from biopsies of CRAMP and
mBD3 were immunostained as described in Materials and Methods. (i and j) mRNA was isolated from epidermis and quantitated by reverse transcription–PCR,
using 18S RNA as standard (see Materials and Methods). (b and f) The levels of CRAMP and mBD3 are at baseline, likely replenished via rapid secretion
of preformed lamellar body contents. (i and j) As expected, there is no significant increase in mRNA levels at this time point. At 4 hours after TS, expression
of CRAMP and mBD3 increases (c and g), which is blocked by occlusion (d and h). This correlates with increased mRNA levels for both CRAMP and
mBD3 at the same time point (i and j). Bars¼ 50 mm.
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2005). By 1–2 hours after acute disruption, substantial
repletion of both CRAMP and mBD3 can be detected
(Figure 1b and f), a finding that correlates with the known
rapid secretion of the pre-formed pool of preformed LB
contents from the stratum granulosum (SG) after acute
disruption (Menon et al., 1992; Elias et al., 1998). By 4 hours
after tape stripping, CRAMP and mBD3 protein levels surpass
pretreatment levels, increasing still further at 8 hours, with
immunodetectable protein declining toward pretreatment
levels by 24 hours (8 and 24 hours data not shown). As seen
in Figure 1i and j, CRAMP and mBD3 mRNA levels also
increase between 1 and 4 hours after tape stripping, but
mBD3 mRNA levels increase more rapidly than do mRNA
levels for CRAMP (Figure 1i and j). Thus, permeability barrier
disruption by tape stripping is followed by rapid reappear-
ance of both AMP protein and mRNA in the epidermis, which
precisely parallels the kinetics of the lipid metabolic response
to permeability barrier disruption (Feingold, 1991).
To assess whether increased AMP expression can be
attributed to permeability barrier perturbation, independent
of method, we next assessed changes in AMP expression after
equivalent degrees of barrier disruption, induced by repeated
acetone wipes. Solvent-induced barrier disruption increases
levels of both mBD3 and CRAMP immunostainable protein,
again between baseline and 8 hours (Figure S1B and E vs A
and D), as following tape stripping (c.f., Figure 1).
Artificial permeability barrier restoration blocks AMP
upregulation
To assess directly the link between AMP expression and
permeability barrier function, we next restored permeability
barrier homeostasis artificially by application of a vapor-
impermeable Latexs membrane, immediately after either
tape stripping or acetone treatment. As with lipid metabolic
responses, artificial barrier restoration blocks the expected,
tape stripping- and acetone-induced increases in both mBD3
and CRAMP protein immunostaining and mRNA expression
(Figure 1d and h, i and j; Figure S1C and F). Thus, acute
alterations in permeability barrier status, regardless of type,
specifically regulate expression of these AMP.
Permeability barrier homeostasis is abnormal in CRAMP
knockout epidermis
Whereas the above studies demonstrate that permeability
barrier requirements regulate both mBD3 and CRAMP
expression, the converse possibility, that is, AMP are required
for permeability barrier homeostasis was next addressed,
assessing permeability barrier function in CRAMP knockout
(k.o.) mice, which display defective resistance to group A
Streptococcus pyogenes (Nizet et al., 2001). Although
CRAMP is not detectable in CRAMP k.o. mice (Figure S3E),
immunostaining of mBD3 in CRAMP/ epidermis greatly
exceeds immunolabelling of this AMP in wild-type (wt) mice
(Figure S3B vs A). Under basal conditions, SC hydration,
surface pH, and basal permeability barrier function, assessed
as TEWL, are all comparable in CRAMP/ and wt mice
(Table S1). To assess whether the permeability barrier is
impaired in CRAMP/ mice, even under basal conditions,
we utilized an alternate, ultrastructural method to assess
permeability barrier function, that is, visualization of the
outward movement of the low-molecular-weight, water-
soluble, electron-dense tracer, colloidal lanthanum nitrate
(Figure 2, curved arrows). While perfused tracer fails to reach
the SG–SC interface in wt mice (Figure 2a and b), lanthanum
moves above the SG–SC interface, breaching the SC in
CRAMP/ mice (Figure 2c). Yet, tracer does not penetrate
across the full thickness of the SC of CRAMP/ mice,
consistent with normal TEWL levels in CRAMP/ epider-
mis. These results demonstrate that CRAMP/ mice display
subtle barrier abnormality, even under basal conditions.
Defective permeability barrier function typically is accen-
tuated when the kinetics of permeability barrier recovery is
assessed after acute disruption (‘‘cutaneous stress test’’)
(Feingold et al., 1991). The kinetics of barrier recovery are
delayed significantly in k.o. versus wt mice at 3 hours
(Po0.001), and apparently also at 6 hours (Po0.07) (Figure 3).
Thus, while the SC of CRAMP/ mice provides a perme-
ability barrier sufficient for survival under basal conditions, it
demonstrates subtle abnormalities even under these non-
stressed conditions; and absence of CRAMP provokes a
marked abnormality in permeability barrier homeostasis.
Abnormalities in the lamellar body secretory system in
CRAMP/ epidermis
The structural basis for the permeability barrier abnormality
in CRAMP/ mice can be attributed to distinctive
SC
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SC
SC
SG SG
SG
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Figure 2. Soluble tracer moves up to and through SC interstices in
CRAMP/ epidermis. In wt epidermis, lanthanum tracer outward egress
(indicated by direction of curved arrows) is blocked at level of SG (a), while
tracer breaches the SG–SC interstices, and focally even above that level, in
CRAMP/ epidermis (c). Six hours after acute barrier disruption by tape
stripping, tracer egress is again impeded at level of outer SG in wt epidermis
(b, curved arrows), indicating restoration of normal barrier function. Yet,
abundant tracer still traverses the entire SC, primarily via the interstices, in
CRAMP/ epidermis (d, arrows). (a–d) Osmium tetroxide post-fixation.
Bars¼ 1 mm (a and c); 0.5 mm (b); and 5 mm (c).
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abnormalities in LB contents and post-secretory membrane
structure under basal conditions, and after acute barrier
disruption, in parallel with delayed barrier recovery kinetics
(c.f., Figure 3). Although the quantities (density) of LB appear
comparable in k.o. versus wt epidermis (Figure 4c, wt not
shown), the internal lamellar cargo of LB is often sparse in
k.o. epidermis (Figure 4c, arrows vs inset (¼wt)). Although
these vacuolated LB appear to undergo exocytosis normally,
they form highly abnormal, electron-lucent vacuoles/clefts at
the SG–SC interface (Figure 4a, asterisks) and c, double
arrows vs 4b, wt; Figure S4C and D). Despite the paucity of
lamellar contents in some LB in CRAMP epidermis, other
proteins (eg, the hydrolytic enzyme, acid lipase) are pack-
aged and secreted from LB normally (Figure S4A and B).
These results demonstrate structural abnormalities in LB
contents in CRAMP/ epidermis.
Using ruthenium tetroxide post-fixation, it is possible to
visualize the post-secretory, structural transformation of
secreted LB contents into the ‘‘mature’’ lamellar membrane
bilayers that regulate the permeability barrier (Elias and
Menon, 1991). Whereas formation of mature lamellar mem-
branes begins at the SG–SC interface (Figures 4b and 5b), and
transformation is completed by the next (¼ second) interspace
in wt epidermis, the formation of ‘‘mature’’ lamellae is both
delayed (Figure 5c, open arrows) and incomplete, that is,
non-transformed LB contents persist high into the SC interstices
in k.o. mice (Figure 5a, open arrows). Even when mature
lamellar structures eventually form (Figure 5a, solid arrows),
they appear foreshortened, and fail to fully engorge the SC
interstices (Figure 5a vs b, solid arrows in wt). Thus, absence of
CRAMP leads to the formation of defective lamellar bilayers.
To assess whether these abnormal-appearing lamellar
membranes account for defective permeability barrier home-
ostasis, we next assessed the pathway of lanthanum tracer
egress through the SC interstices of CRAMP/ versus wt
mice. By 6 hours after acute barrier disruption, wt SC
completely excludes lanthanum (Figure 2b), as under basal
conditions (c.f.; Figure 2a), and consistent with the 450%
barrier recovery in wt (and normal) murine epidermis at
6 hours (c.f.; Figure 3). In contrast, tracer still fully permeates
the SC interstices in CRAMP/ epidermis at 6 hours (Figure
2d), consistent with the delay in permeability barrier recovery
at this time point (c.f., Figure 3). Since the tracer moves across
the SC of k.o. mice solely through extracellular domains (c.f.;
Figure 2d), abnormal lamellar membrane architecture ac-
counts for the permeability barrier abnormality (c.f.; Figure 5).
Together, these studies provide a structural basis for the
permeability barrier abnormality in CRAMP/ mice,
demonstrating that CRAMP is critical for the formation of
functionally competent, extracellular lamellar bilayers.
DISCUSSION
We assessed the relationship between permeability barrier
function and antimicrobial defense in mammalian epidermis,
because barrier function can be perturbed incrementally by
well-defined methods, such as solvent/detergent treatment or
tape stripping (Feingold, 1991). The SC of mammalian
epidermis, which subserves several protective functions (Elias
et al., 2003; Elias, 2005), comprises a heterogeneous
structure of anucleate corneocytes embedded in a lipid-
enriched, extracellular matrix (Elias and Friend, 1975; Elias,
1983; Elias and Menon, 1991), important for the permeability
barrier. The extracellular matrix also contains two AMP,
which contribute to antimicrobial defense. Both hBD2 and
LL-37, the human homologues of mBD3 and CRAMP, are
sequestered in LB (Oren et al., 2003; Braff et al., 2005), and
their secretion is supported by a membrane pattern of
immunostaining for hBD2 in human SC (Huh et al., 2002).
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Figure 3. CRAMP k.o. mice display a significant delay in permeability
barrier recovery after tape stripping. Barrier recovery after tape stripping
was compared in 6-week old CRAMP (Cnl-1-) k.o. versus wt mice (29). Mice
were shaved 24hours before tape stripping, which was repeated until TEWL
rates X10-fold normal levels. The extent of permeability barrier recovery,
as percent of the original abnormality, was assessed 3 and 6 hours after
tape stripping.
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Figure 4. Abnormalities LB secretory system in CRAMP/ epidermis.
(a, c, and e) CRAMP/ epidermis. (b and d, inset) wt epidermis. Under basal
conditions, CRAMP/ epidermis reveals abnormalities in contents of
individual LB (c, single arrows). In contrast, wt epidermis has LB with replete
contents (d, inset, arrowheads). In the CRAMP/mouse epidermis, there are
non-lamellar clefts within secreted LB contents at the SG–SC interface
(a, asterisks; c and e, double arrows). In wt epidermis, transformation of
secreted LB contents into lamellar bilayers already occurs at SG–SC interface,
as demonstrated in (b) (arrows). (a and b) Ruthenium textroxide post-fixation;
(c and d) osmium tetroxide post-fixation. Bars¼ 0.2 mm (a and b); 1mm (c and
e); and 0.1 mm (d, inset).
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Although the constitutive expression of both of these
peptides is low (Frohm et al., 1997; Liu et al., 2002; Heilborn
et al., 2003; de Jongh et al., 2005; Mallbris et al., 2005;
Sorensen et al., 2005; Weber et al., 2005), substantial protein
is present in the outer layers of unperturbed murine
epidermis, consistent with their dual roles in antimicrobial
defense (Elias, 2007), and the innate immune system
(Schroder, 1999; Gallo et al., 2002; Ganz, 2002; Izadpanah
and Gallo, 2005; Lehrer, 2005). Finally, the increased severity
of cutaneous streptococcal infections in CRAMP/ mice
clearly demonstrates that constitutive levels of CRAMP are
critical for antimicrobial defense (Nizet et al., 2001).
Several results here support the hypothesis that the
permeability and antimicrobial barriers of the SC may not
be discrete (Elias, 2005; Elias and Choi, 2005), but rather
coregulated and even interdependent functions; (1) the AMP
metabolic response parallels the lipid metabolic response to
acute permeability barrier disruption. When the permeability
barrier is perturbed by solvent treatment or tape stripping, a
sequential, lipid-synthetic response ensues in the underlying
epidermis that rapidly restores normal permeability barrier
homeostasis (Feingold, 1991). Acute barrier perturbation is
followed sequentially by rapid secretion (within 30minutes)
of much of the preformed pool of LB (Menon et al., 1992;
Elias et al., 1998); transcriptional upregulation of epidermal
cholesterol, fatty acid, and ceramide synthesis (1–9 hours)
(Holleran et al., 1991; Proksch et al., 1993; Ottey et al.,
1995); further LB production (2–6 hours) (Menon et al., 1992);
increased production of lipid hydrolases, necessary to
generate lamellar membranes (9–12 hours) (Holleran et al.,
1994); and increased DNA synthesis (16–24 hours) (Proksch
et al., 1991). Yet, permeability barrier disruption not only
removes lipids (Grubauer et al., 1989b), but it also initiates a
parallel, rapid loss of AMP from SC (Elias and Choi, 2005).
We show here that subsequent changes in AMP protein
and mRNA levels upregulate in parallel with the lipid
metabolic response. While some AMP protein is restored
rapidly to the SC, presumably by secretion of the preformed
pool of LB (p60minutes) (Menon et al., 1992; Elias et al.,
1998). mRNA and protein for both AMPs begin to increase
1–4 hours after acute disruption, peaking by 4–8hours, and
returning to basal levels by 24 hours in parallel with
permeability barrier normalization after acute perturbations
(Menon et al., 1985; Grubauer et al., 1989b). In addition,
similar kinetics of AMP production occur, independent
of the method of barrier disruption, that is, tape stripping or
organic solvent treatment. The most specific evidence
that AMP expression is linked inextricably to the permeability
barrier is shown by the blockade of the expected upregulation
of AMP expression following artificial restoration of the
permeability barrier with a vapor-impermeable membrane.
Blockage of the increase in epidermal lipid synthesis and
secretion by occlusion is the ‘‘gold standard’’ that links
metabolic responses in the underlying epidermis specifically
to permeability barrier function (Feingold, 1991). Thus, the
parallel AMP metabolic and lipid metabolic responses comprise
initial evidence that AMP expression is regulated by changes in
permeability barrier status.
Further evidence for a link between permeability barrier
function and AMP expression is supported by reports that the
human homologues of these AMP, which are cargo within LB,
are upregulated in psoriasis (Frohm et al., 1997; Ong et al.,
2002b; de Jongh et al., 2005; Harder and Schroder, 2005), a
disorder characterized by permeability barrier abnormalities
that parallel disease severity (Ghadially et al., 1996).
The intimate link between these two functions is likely due
to the coassembly of AMP (Oren et al., 2003; Braff et al.,
2005), with barrier lipid precursors (Grayson et al., 1983,
1985), within nascent LB. Coassembly of lipids and AMP
could be interdependent, because protein delivery to
epidermal LB requires prior lipid deposition (Rassner et al.,
1999). Finally, the interrelationship of these two functions is
shown further by the fact that certain SC lipids, such as free
fatty acids and ceramide metabolite (sphingosine), display
potent antimicrobial activity (Miller et al., 1988; Bibel et al.,
1992). Finally, secreted LB contents provide a formidable
physical barrier (Elias, 2007) that both excludes exogenous
pathogens, and conversely offers the path of least resistance
for penetration of most microbes through compromised SC
(Miller et al., 1988). Thus, when the lamellar matrix is
abnormal (as in atopic dermatitis) (Fartasch et al., 1993;
Chamlin et al., 2002), pathogens can penetrate due to the
more ‘‘porous’’ nature of the SC interstices.
Utilizing CRAMP/ mice, which display defective,
cutaneous antimicrobial defense, particularly against
S. pyogenes (Nizet et al., 2001), we also showed the converse,
that is, at least one AMP, CRAMP, is required for normal
permeability barrier function. Thus, in addition to its dual role
as an antimicrobial agent and signal of the innate immune
system, CRAMP displays an additional, critical structural role.
Although CRAMP/ mice display normal levels of TEWL
KO
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SC WT
SC
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Figure 5. Delayed and incomplete formation of lamellar bilayers in
CRAMP/ epidermis. In wt epidermis under basal conditions, secreted LB
contents transform into lamellar bilayers within the SG–SC interface (b, solid
arrows). In contrast, secreted lamellar contents remain partially
untransformed several layers above SG-SC interface (a and c, open arrows),
within SC interstices of CRAMP/ mice. Moreover, lamellar bilayers, when
present in SC of k.o. mice, fail to fill interstices (a, solid arrows). (a–c)
Ruthenium textroxide post-fixation. Bars¼ 0.2 mm.
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under basal conditions, tracer perfusion studies demonstrate
subtle functional abnormalities, even under these conditions.
More importantly, after the stress of acute barrier disruption,
CRAMP/ mice demonstrate a highly significant delay in
barrier recovery kinetics, consistent with a role for this AMP
in the maintenance of permeability barrier homeostasis. This
so-called ‘‘cutaneous stress test’’ reveals pathology in several
clinical settings, where basal function is (misleadingly)
normal (Ghadially et al., 1995; Altemus et al., 2001; Garg
et al., 2001; Fluhr et al., 2004). Importantly, where the
‘‘cutaneous stress test’’ reveals abnormalities, it is usually
possible to delineate the metabolic and/or structural basis for
defective function, because the ‘‘stress test’’ amplifies the
functional abnormalities (Elias, 2005). Accordingly, abnormal
permeability barrier function correlates with abnormalities in
both LB contents and in the extracellular lamellar membrane
structure in CRAMP/ epidermis. It is possible that CRAMP
interacts with more hydrophobic, LB-derived, pro-barrier
lipids in a manner that facilitates the dispersion or organiza-
tion of secreted lipids into the lamellar bilayers that subserve
the permeability barrier (Elias and Menon, 1991). Since
CRAMP, like mBD3 and certain other AMP, is a low-
molecular-weight, highly hydrophobic peptide (Schroder,
1999; Ganz, 2002; Izadpanah and Gallo, 2005), it could
provide critical, amphiphilic constituents that maintain the
extracellular, lamellar membrane system, while still remain-
ing bioavailable, because it does not completely integrate
into the hydrophobic core of lipid bilayers (Henzler Wildman
et al., 2003). Pertinently, the apparent, compensatory
upregulation of mBD3 protein in CRAMP/ mice does
not suffice to correct the barrier abnormality, suggesting a
specific requirement for CRAMP for permeability barrier
homeostasis. Finally, two class II nuclear hormone receptor
ligands, retinoids and 1,25(OH)2 vitamin D3, display
divergent effects on epidermal differentiation (Elias et al.,
1981; Pillai and Bikle, 1991), with parallel regulation of
hCAP and hBD2 expression, consistent with the link between
epithelial integrity and AMP expression in extracutaneous
tissues (Weber et al., 2005; Zasloff, 2005; Nenci et al., 2007).
For example, abnormal mucosal permeability leads to
inflammatory bowel disease in transgenic mice with deletion
of the antimicrobial cytokine, resistin-like molecule-b (Hogan
et al., 2006), and a similar relationship may pertain to
patients deficient in CARD15 (Buhner et al., 2006), a-
defensin, or REGIIIg production (Strober, 2006). Since LL-37
and hBD2 are also produced by airway epithelial cells (Bals
et al., 1998a, b), and since these peptides fail to upregulate in
atopic dermatitis (Ong et al., 2002a), a deficiency in LL-37/
hBD2 could weaken respiratory epithelial integrity, sufficient
to allow infectious triggers of asthma.
MATERIALS AND METHODS
Murine models
Female hairless mice (Skh1/Hr), 8 weeks of age, were purchased
from Charles River Laboratories (Wilmington, MA). CRAMP k.o.
mice (Cnl-1-) and wt mice were prepared on a 127/SvJ background
(Nizet et al., 2001). All animal protocols were approved by the
Animal Research Committee, SFVAMC. Mice were maintained in a
temperature- and humidity-controlled room, and given standard
laboratory food and tap water ad libitum. Mice were subjected to
acute barrier disruption by either tape stripping or acetone wipes,
and left either air-exposed or immediately covered with a vapor-
impermeable (Latex) membrane (Grubauer et al., 1989a).
Functional studies
Surface pH was measured under basal conditions with a flat, glass
surface electrode from Mettler-Toledo (Columbus, OH), attached to a
pH meter (PH 900; Courage and Khazaka). SC hydration was
quantitated as changes in electrical capacitance in arbitrary units
(Corneometer CM 820; Courage and Khazaka, Ko¨ln, Germany) in the
basal state of both wt and CRAMP/mice. The mean of three separate
measurements on each animal was utilized for statistical comparisons.
TEWL in the basal state was measured as p.p.m./cm2/hour with an
electrolytic water analyzer (Meeco, Warrington, PA) (Grubauer et al.,
1989a). Barrier recovery kinetics were compared by measuring TEWL
immediately after 3, 6, and 24hours following acute barrier disruption
by either tape stripping or acetone treatment (Grubauer et al., 1989a).
Tissue preparation, protein, and RNA isolation
Skin samples were obtained immediately after, 4, 8, or 24 hours
following tape stripping or acetone treatment of normal hairless
mice, with or without prior occlusion, as above, and from CRAMP/
versus wt littermates. Epidermis was obtained by EDTA separation,
and total RNA was extracted with a commercially available kit,
RNeasy Mini RNA isolation kit from Qiagen (Valencia, CA). RNA
solution (50 ml) was reverse-transcribed to cDNA (Horikoshi et al.,
1992), and real-time quantitative PCR was performed for mBD3,
CRAMP, and 18S (internal control) in triplicate on an ABI 7900
machine, using the SYBR green detection kit from Applied
Biosystems (Foster City, CA), (Tirmenstein et al., 2000). Primer
sequences were as follows: mBD3 fw: ATTTCTCCTGGTGCTCGTGT
3, rev: GGAACTCCACAACTGCCAAT; and 18S fw: GTAACCCGT
TGAACCCCATT, rev: CCATCCAATCGGTAGTAGCG. The mBD3
and 18S PCR primers were synthesized by Biosearch Technologies
(Novato, CA), while murine cathelicidin primers were from Richard
Gallo. Standard reaction volumes were 20 ml with 250 ng cDNA and
125nM of mBD3, 500 nM of 18S, or 1mM final concentration of
cathelicidin primers. Initial steps of reverse transcription–PCR
(RT–PCR) were 2minutes at 501C, followed by a 10minutes at
951C. Cycles (n¼ 40) consisted of a 15-second melt at 951C, followed
by a 300-second annealing/extension at 601C. Threshold (Ct) analysis
for all samples was set at 0.50 relative fluorescence units. Quantitative
polymerase chain reaction (QPCR) data were analyzed using the
2DDCt method (Winer et al., 1999; Schmittgen et al., 2000).
Western immunoblotting
For Western blotting, low-molecular-weight, hydrophobic, cationic
peptides were extracted, and separated from full-thickness mouse
skin in 10mM EDTA (Schroder, 2001). Extractions were performed in
an acidic buffer (30% acetonitrile, 0.1% formic acid; pHo3);
extracts were homogenized on ice, centrifuged at 14,000 r.p.m. for
30minutes at 41C, and supernatants were re-centrifuged for
15minutes before protein fractionation. An equal amount of
extracted protein in NuPAGE sample buffer in water was heated at
851C, without reducing agents, followed by loading of equal
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amounts of samples from each experimental group onto 12% tricine
gels (Invitrogen, Carlsbad, CA), using b-actin as an internal standard.
After electrophoresis, proteins were transferred from gels onto
polyvinylidene difluoride membranes and electrophoresed for 1 hour
in tricine/glycine transfer buffer, followed by immunoblotting with
the rabbit anti-mouse mBD3 antibody (Alpha Diagnostics, San
Antonio, TX). Antibody binding to mBD3 was detected with the
Western-Breeze chemiluminescence kit, following the manufac-
turer’s protocol (Invitrogen).
Electron microscopy
Skin biopsies were taken from CRAMP/ and wt mice in the basal
state, and processed as described for 0.5% ruthenium tetroxide (RuO4)
and 2% aqueous osmium tetroxide (OsO4), post-fixation (Hou et al.,
1991). Samples then were dehydrated in graded ethanol solutions and
embedded in an Epon-epoxy mixture. Prior to post-fixation, some
samples were processed for ultrastructural cytochemistry, utilizing
triacylglycerol lipase as an alternate marker of protein assembly and
secretion from LB (Rassner et al., 1999). Some fresh biopsies were
submerged en bloc in 4% colloidal lanthanum nitrate, which serves as
an electron-dense tracer of water movement through the epidermis
(Hanley et al., 1997; Elias et al., 2002), and post-fixed in osmium
tetroxide. Ultrathin sections were examined, with or without further lead
citrate contrasting, in Zeiss 10A electron microscope, operated at 60kV.
Immunofluorescence and immunohistochemistry
Freshly obtained skin biopsies were snap frozen in liquid nitrogen,
and stored in a tissue-embedding medium. Frozen sections (8 mm)
were soaked in acetone for 10minutes, washed in phosphate-
buffered saline, and blocked with 4% BSA and 0.05% cold fish
gelatin in phosphate-buffered saline for 30minutes. Slides were
incubated overnight at 41C with CRAMP (from Richard Gallo) or
mBD3 primary antibodies, followed by incubation with an FITC-
conjugated goat anti-rabbit, secondary antibody (Alpha Diagnostic,
no. 5) for 40minutes at room temperature. Slides were counter-
stained with propidium iodide for nuclear visualization and
examined on a Leica TCS-SP confocal microscope.
Data were expressed as means7SE. Statistical analyses were
performed using paired and unpaired Student’s t-tests.
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SUPPLEMENTARY MATERIAL
Table S1. CRAMP/ mice display no significant differences in either
hydration, surface pH, or basal TEWL.
Figure S1. Acute permeability barrier disruption by an alternative method
(acetone treatment) stimulates CRAMP/mBD3 expression; upregulation again
is blocked by occlusion.
Figure S2. Western immunoblotting reveals a single band corresponding to
mBD3 in normal mouse epidermis.
Figure S3. Compensatory increase in mBD3 protein in CRAMP/ epidermis.
Figure S4. Normal content and secretion of another lamellar body protein in
CRAMP/ epidermis.
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